700 patients to reveal how new arthritis drugs perform in the real world
Knowledge-focused
Recruiting now
This study will follow 700 adults with axial spondyloarthritis or psoriatic arthritis who have recently started one of several newer treatments (bimekizumab, upadacitinib, risankizumab, guselkumab, or a TNF inhibitor). Researchers will collect medical records and patient surveys …
Sponsor: Adelphi Real World • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:21 UTC